ES2138602T3 - Agente terapeutico para la amenaza de aborto. - Google Patents

Agente terapeutico para la amenaza de aborto.

Info

Publication number
ES2138602T3
ES2138602T3 ES93103300T ES93103300T ES2138602T3 ES 2138602 T3 ES2138602 T3 ES 2138602T3 ES 93103300 T ES93103300 T ES 93103300T ES 93103300 T ES93103300 T ES 93103300T ES 2138602 T3 ES2138602 T3 ES 2138602T3
Authority
ES
Spain
Prior art keywords
abortion
threat
therapeutic agent
coagulation
human blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93103300T
Other languages
English (en)
Inventor
Takaaki Nakaya
Yayoi Kajiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of ES2138602T3 publication Critical patent/ES2138602T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UN AGENTE TERAPEUTICO PARA POSIBLE ABORTO QUE CONTIENE FACTOR XII DE COAGULACION DE SANGRE HUMANA COMO EL INGREDIENTE ACTIVO. FACTOR XII DE COAGULACION DE SANGRE HUMANA ADMINISTRADO A PACIENTES CON AMENAZA DE ABORTO TRATA CON EXITO LA ENFERMEDAD, Y SUS EFECTOS SON NOTORIOS.
ES93103300T 1992-03-06 1993-03-02 Agente terapeutico para la amenaza de aborto. Expired - Lifetime ES2138602T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP04935392A JP3337488B2 (ja) 1992-03-06 1992-03-06 切迫流産治療剤

Publications (1)

Publication Number Publication Date
ES2138602T3 true ES2138602T3 (es) 2000-01-16

Family

ID=12828657

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93103300T Expired - Lifetime ES2138602T3 (es) 1992-03-06 1993-03-02 Agente terapeutico para la amenaza de aborto.

Country Status (11)

Country Link
US (1) US5554593A (es)
EP (1) EP0559145B1 (es)
JP (1) JP3337488B2 (es)
KR (1) KR100255095B1 (es)
AT (1) ATE185274T1 (es)
AU (1) AU657839B2 (es)
CA (1) CA2091134C (es)
DE (1) DE69326627T2 (es)
DK (1) DK0559145T3 (es)
ES (1) ES2138602T3 (es)
GR (1) GR3032224T3 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339964T1 (de) * 1997-05-15 2006-10-15 Trillium Therapeutics Inc Verfahren um immunkoagulation zu modulieren
US6642433B1 (en) 1997-05-15 2003-11-04 Trillium Therapeutics Inc. Fgl-2 knockout mice
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1933852B1 (en) 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
CA2837878A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016138025A2 (en) 2015-02-23 2016-09-01 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CN107847526A (zh) 2015-05-20 2018-03-27 组织技术公司 用于预防上皮细胞的增殖和上皮‑间充质转换的组合物和方法
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPH03240738A (ja) * 1990-02-20 1991-10-28 Hoechst Japan Ltd 糖尿病性壊疽治療剤

Also Published As

Publication number Publication date
EP0559145A1 (en) 1993-09-08
EP0559145B1 (en) 1999-10-06
CA2091134C (en) 2004-04-06
CA2091134A1 (en) 1993-09-07
DE69326627T2 (de) 2000-02-17
JP3337488B2 (ja) 2002-10-21
US5554593A (en) 1996-09-10
AU657839B2 (en) 1995-03-23
KR930019224A (ko) 1993-10-18
JPH05246886A (ja) 1993-09-24
KR100255095B1 (ko) 2000-05-01
DK0559145T3 (da) 2000-04-10
DE69326627D1 (de) 1999-11-11
GR3032224T3 (en) 2000-04-27
ATE185274T1 (de) 1999-10-15
AU3401093A (en) 1993-09-09

Similar Documents

Publication Publication Date Title
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
NO20034684D0 (no) Innretning for administrering av midler gjennom stratum corcum
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ATE69376T1 (de) Haarwuchsmittel.
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
UY23665A1 (es) Procedimiento para la preparacion de compuesto farmaceutico
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
PT90049A (pt) Forma de dosagem para administrar um medicamento para terapia humana
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
KR910009242A (ko) 치근막 질환 치료용 서방성 조성물
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
AR097737A2 (es) Agente preventivo y/o terapéutico para enfermedades inflamatorias del tracto respiratorio
ES2184145T3 (es) Compuestos de acido sulfonico o sulfonilamino-n-(heteroaralquil)-azaheterociclilamida.
ES2138602T3 (es) Agente terapeutico para la amenaza de aborto.
PT998287E (pt) Utilizacao de levobupivacaina
AR001073A1 (es) Benzoilguanidinas basicamente sustituidas procedimientos para su preparación su empleo como medicamento o agente de diagnostico asi como medicamento que las contiene
ES2050653T3 (es) Tableta de granulos multiples, de emision sostenida.
ES2042818T3 (es) Agente terapeutico para la trombocitopenia.
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
AR003979A1 (es) Administracion transdermica de vorozol.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
KR930702016A (ko) 골다공증 치료제
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 559145

Country of ref document: ES